Description
Book SynopsisIn recent years, the understanding of the pathophysiological processes of atherosclerosis, a chronic inflammatory disease of the vessel wall being the leading cause for mortality in industrial countries, has tremendously increased. The feasibility of translating such knowledge to novel therapeutic approaches is currently being explored at various levels. This book highlights advances in atherosclerosis and links these to relevant therapeutic strategies. It compiles and details cutting-edge research in cardiovascular medicine from internationally renowned authors.
Table of ContentsNovel approaches in treatment of atherosclerosis. Chemokines as therapeutic targets of atherosclerosis. MIF antagonism as a therapeutic approach to atherosclerosis. Peptide-based vaccination strategies to promote Treg- or antibody-mediated atheroprotection. Modulation of prostanoids in the treatment of atherosclerosis. Stabilization of mast cells for taming vulnerable plaques. HDL, ABC transporters, and cholesterol efflux as therapeutic targets in atherosclerosis. Role of selective phospholipase A2 inhibition in the treatment of atherosclerosis. Modulation of the rennin-angiotensin system in atherosclerosis. Role of matrix metalloproteases as targets for the prevention of atherosclerosis. Probucol-derivates in the treatment of atherosclerosis. Interference with apoptosis and ER stress in the treatment of atherosclerosis. MicroRNAs in the pathogenesis and therapy of atherosclerotic vascular disease. Neutrophils and their granule proteins in the treatment of atherosclerosis. Platelets in the treatment of atherosclerosis. Costimulatory molecules in the treatment of atherosclerosis.
